|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Therefore, we also investigated the dynamic of other protein markers involved in cognition and memory impairment such as metabotropic glutamate receptor 5 (mGluR5), ionotropic NMDA receptor (NMDAR2B), prion protein (PrPc) and amyloid precursor protein (APP), whose activity depends on membrane lipid organization.
|
31068782 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Microglia and amyloid precursor protein coordinate control of transient Candida cerebritis with memory deficits.
|
30610193 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Selectively inhibiting Aβ-induced PIP<sub>2</sub> hydrolysis in the CA3 region of the hippocampus strongly prevents oligomeric Aβ-induced suppression of Pr at the SC-CA1 synapse and rescues synaptic and spatial learning and memory deficits in APP/PS1 mice.
|
30867420 |
2019 |
|
Memory impairment
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
We show that prolonged treatment with selegiline fails to reduce aberrant astrocytic GABA levels and rescue memory impairment in APP/PS1 mice, an animal model of AD, because of increased activity in compensatory genes for a GABA-synthesizing enzyme, diamine oxidase (DAO).
|
30906861 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
We observed that Aβ<sub>1-42</sub> could induce spatial learning and memory deficits in rats.
|
31016510 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Tolfenamic acid is a nonsteroidal anti-inflammatory drug with neuroprotective properties, and it alleviates learning and memory deficits in the APP transgenic mouse model of Alzheimer's disease.
|
31049134 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Importantly, we show that restoration of Cav-1 levels in the brains of male <i>db/db</i> mice using adenovirus overexpressing Cav-1 (AAV-Cav-1) rescues learning and memory deficits and reduces pathology (i.e., APP, BACE-1 and p-tau levels).
|
31527120 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Results showed that spatial learning and memory deficits were improved in curcumin-treated APP/PS1 mouse group compared with those in APP/PS1 mice group.
|
30312017 |
2019 |
|
Memory impairment
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
Our results showed that IFNβ treatment reduced APP expression and Aβ plaque formation, and concomitantly ameliorated spatial learning and memory deficits examined in Y-maze and Morris water maze tests.
|
31152860 |
2019 |
|
Memory impairment
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
More severe learning and memory impairment and higher Aβ1-40 expression in brain and plasma were detected in the APP/PS1 mice of 27-OHC treatment group.
|
30582229 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, treatment with albiflorin improved mitochondrial function, reduced Aβ deposition in the brain and ameliorated memory deficits in APP/PS1 mice.
|
31150651 |
2019 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions.
|
30050407 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Increased ILK expression of dentate gyrus (DG) rescued the hippocampus-dependent neurogenesis and memory deficits in APP/PS1 mice.
|
29787769 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Here, we confirmed that four weeks' treatment of exendin-4 could rescue memory deficits and neuropathological changes in APP/PS1 mice.
|
29223528 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
An efficacy test carried out in APP/PS1 transgenic mice showed a reduction of memory deficit in mice chronically treated with PGZ-NPs.
|
30271148 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Xanthoceraside administration alleviated learning-memory deficits and increased the LTP in APP/PS1 transgenic mice.
|
29124300 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Virgin coconut oil (VCO) by normalizing NLRP3 inflammasome showed potential neuroprotective effects in Amyloid-β induced toxicity and high-fat diet fed rat.
|
29729307 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
APP/PS1 mice and KCa3.1<sup>-/-</sup>/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits.
|
30442153 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Flavonoids extracted from leaves of Diospyros kaki regulates RhoA activity to rescue synapse loss and reverse memory impairment in APP/PS1 mice.
|
29481523 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
The results demonstrated that EA treatment ameliorated spatial learning and memory impairment in APP/PS1 mice and significantly reduced neuronal apoptosis and Aβ deposition in the hippocampus (P<0.05 and P<0.01).
|
30542451 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer's disease-like pathology.
|
29241655 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Our data suggest that metformin can exert functional recovery of memory deficits and neuroprotective effect on APP/PS1 mice via triggering neurogenesis and anti-inflammation mediated by regulating AMPK/mTOR/S6K/Bace1 and AMPK/P65 NF-κB signaling pathways in the hippocampus, which may contribute to improvement in neurological deficits.
|
29253574 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
The results showed that treatment with TA significantly reversed the memory deficit in the APP/PS1 mice in a spatial water maze test.
|
29050859 |
2018 |
|
Memory impairment
|
0.500 |
AlteredExpression
|
phenotype |
BEFREE |
Results reveal that SMC 1) reduces oxidative stress and neuro-inflammation; 2) modulates the distribution and levels of several metal ions; 3) decreases amyloid-β peptide (Aβ) generation by inhibiting the expression of its precursor protein APP and β-secretase (BACE1); and 4) attenuates tau hyperphosphorylation and neurofibrillary tangles (NFT) formation via promoting protein phosphatase 2A (PP2A) activity, thereby preserving synaptic proteins and neuron activities and finally improving spatial learning and memory deficits in AD model mice.
|
29688618 |
2018 |
|
Memory impairment
|
0.500 |
Biomarker
|
phenotype |
BEFREE |
Pharmacodynamics studies demonstrated that chronic oral administration of 8d·HCl substantially ameliorated the cognitive and spatial memory deficits in APP/PS1 AD mice and noticeably reduced overall cerebral β-amyloid deposits.
|
29420891 |
2018 |